Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a year-on-year growth of 15%[7]. - The company's operating revenue for the reporting period reached ¥4,979,904,160.12, representing a 40.17% increase compared to ¥3,552,801,943.59 in the same period last year[13]. - Net profit attributable to shareholders was ¥1,494,018,135.83, marking an 89.64% increase from ¥787,865,631.16 in the previous year[13]. - The net profit after deducting non-recurring gains and losses was ¥1,255,155,334.33, which is a 96.19% increase compared to ¥639,827,802.69 in the same period last year[13]. - The overall gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management and pricing strategies[7]. - Operating profit reached 1.80 billion yuan, up 94.71% year-on-year, while net profit attributable to shareholders was 1.49 billion yuan, reflecting an 89.64% increase[26]. - The cash flow from operating activities was 1.50 billion yuan, a 61.73% increase compared to the previous year[26]. - The company's gross profit margin was 51.68%, an increase of 4.44% year-on-year[28]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting a 25% increase in market share within the next year[7]. - The company has set a revenue guidance for the second half of 2023, projecting an increase of 10% compared to the first half[7]. - The company is exploring acquisition opportunities to enhance its product portfolio and expand its technological capabilities[7]. - The company aims to enhance its product offerings through continuous innovation in technology, focusing on stability, noise reduction, and lightweight designs in its oxygen machines[19]. - The company is actively incubating high-potential businesses in emergency care, ophthalmology, and intelligent rehabilitation, indicating a strategic expansion approach[19]. - The company has completed several acquisitions, enhancing its product portfolio to over 600 types and nearly 10,000 specifications[30]. Research and Development - Research and development investments have increased by 18%, focusing on advanced medical technologies and smart healthcare solutions[7]. - The company invested 274 million yuan in R&D, a 6.00% increase year-on-year, while managing expenses effectively[28]. - The company aims to enhance its research and development capabilities to innovate new technologies and products[111]. Product and Market Focus - The company focuses on providing home medical devices and clinical products, with R&D, manufacturing, and sales as its core business[18]. - The company focuses on three core areas: respiratory and oxygen therapy, diabetes management, and infection control, with significant experience in R&D, manufacturing, and sales[19]. - The respiratory therapy solutions business grew by 109.99%, with oxygen machine sales increasing by 140% and respiratory machine sales exceeding 110%[26]. - The diabetes care solutions business saw a revenue increase of 31.07%, with the successful market launch of a 14-day no-calibration CGM product[26]. - The company has launched the "Anai Sugar" continuous glucose monitoring product, leveraging its scale and technological capabilities to enhance its diabetes business[21]. - The infection control business has over 400 products and has become a leading brand in hospital disinfection, driven by increased public health awareness and demand for comprehensive disinfection solutions[22]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year, opting to reinvest profits into growth initiatives[2]. - The company reported non-recurring gains totaling ¥238,862,801.50, which includes gains from the disposal of non-current assets and government subsidies[16]. - The company has established effective risk control measures for its foreign exchange hedging activities, ensuring compliance with legal requirements[44]. - The company has not engaged in speculative derivative investments during the reporting period[45]. - The company reported a financial income of ¥19,546,416.24, down from ¥96,625,683.67 in the previous year, indicating a decrease of approximately 80%[101]. Risk Management - The management has identified potential risks in the industry, including regulatory changes and supply chain disruptions, and is implementing strategies to mitigate these risks[2]. - The company has implemented internal control measures to manage risks associated with derivative investments, with no significant risks reported during the period[44]. - The company is actively working on compliance and management improvements following the administrative penalty, ensuring adherence to legal standards[69]. Shareholder Information - The company has not engaged in any related party transactions during the reporting period, maintaining a clear operational focus[71]. - The company has not reported any non-operating fund occupation by major shareholders or related parties during the reporting period, ensuring financial integrity[65]. - A total of 6,622,216 shares were acquired under the employee stock ownership plan at a price of 22.5 CNY per share, with an estimated total expense of 88.14 million CNY recognized[57]. - The company’s directors and senior management hold a total of 6,622,216 shares, representing 0.66% of the total share capital[54]. Compliance and Legal Matters - The company has not faced any administrative penalties related to environmental issues during the reporting period[60]. - The company has faced a regulatory penalty of 2.7 million yuan due to price increases of its YX306 pulse oximeter exceeding cost growth, but it does not expect this to significantly impact overall performance[69]. - There were no significant lawsuits or arbitration matters reported during the period, indicating a stable legal environment for the company[67]. Environmental and Social Responsibility - The company donated thousands of oxygen machines to grassroots health institutions in central and western regions and over 10,000 medical-grade oxygen machines to more than 800 impoverished counties[61]. - The company actively promotes green and environmentally friendly practices, including paperless office initiatives[60].

独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管 要求》、《深圳证券交易所股票上市规则》等相关规定和要求，作为江苏鱼跃医 疗设备股份有限公司（以下简称"公司"）的独立董事，本着对公司、全体股东 及投资者认真、负责的态度，根据实事求是的原则，对公司2023年半年度的对外 担保情况和控股股东及其他关联方资金往来的情况进行了认真的检查核实，基于 独立判断立场，发表如下独立意见： 公司当期不存在控股股东及其他关联方违规占用公司资金的情况，也不存在 以前年度发生并累计至 2023 年 6 月 30 日的控股股东及其他关联方违规占用资 金情况。公司当期不存在为控股股东及其他关联方提供担保的情况，公司无逾期 担保、涉及诉讼的担保或因担保被判决败诉而应承担损失的情况。 江苏鱼跃医疗设备股份有限公司 独立董事对第五届董事会第七次会议相关事项的 独立董事：于春 钟明霞 万遂人 二〇二三年八月二十八日 ...

江苏鱼跃医疗设备股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | 2023 年 1-6 | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用 | 占用方与 上市公司 | 上市公司核 | 2023 年期初 | 月占用累计 | 2023 年 6 月占用资 | 1- | 2023 年 1-6 | 2023 年 6 | 占用形成 | | | 非经营性资金占用 | 方名称 | | 算的会计科 | 占用资金余 | 发生金额 | | | 月偿还累计 | 月 30 日占 | 原因 | 占用性质 | | | | 的关联关 | 目 | 额 | （不含利 | 金的利息 | | 发生金额 | 用资金余额 | | | | | | 系 | | | 息） | （如有） | | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-029 江苏鱼跃医疗设备股份有限公司 关于 2021 年度第一期员工持股计划第二个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）于 2021 年 6 月 17 日召开第五届董事会第八次临时会议和第五届监事会第四次临时会议，于 2021 年 7 月 5 日召开 2021 年第一次临时股东大会，审议通过了《公司 2021 年度第一期员工持 股计划（草案）及其摘要》等相关议案。具体内容详见公司于 2021 年 6 月 18 日和 2021 年 7 月 6 日披露在《证券时报》及巨潮资讯网（www.cninfo.com.cn）上的相关公告。 公司 2021 年度第一期员工持股计划（以下简称"本次员工持股计划"）第二个锁定 期于 2023 年 8 月 26 日届满，根据中国证监会《关于上市公司实施员工持股计划试点的 指导意见》、《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 的相关规定，现将本次员工 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2023-028 江苏鱼跃医疗设备股份有限公司 关于子公司土地收储有关事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易情况概述 为加快推进旧区改造，实施城市规划，上海市虹口区土地发展中心（以下简 称"虹口土发中心"）对江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗" 或"公司"）子公司上海医疗器械（集团）有限公司手术器械厂（以下简称"上 手厂"）名下的上海市虹口区粤秀路 351 号地块相关国有土地使用权、房屋、地 上及地下建筑物/构筑物实施收储（以下简称"本次收储"或"本次交易"）。 公司、上手厂于 2022 年 12 月 9 日与虹口土发中心就本次收储签订《收购粤 秀路 351 号地块国有土地使用权补偿合同》（以下简称"收购土地使用权补偿合 同"），约定收储土地面积 38,490 平方米，建筑面积 29,457 平方米，搭建面积 5,574.7 平方米，约定综合补偿金额为人民币 999,869,000.00 元（大写：人民币玖 亿玖仟玖佰捌拾陆万玖仟元整）。 截至 2022 年 ...

证券代码：002223 证券简称：鱼跃医疗 江苏鱼跃医疗设备股份有限公司投资者关系活动记录表 编号：2023-5-12 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 活动参与人员 | 线上参与 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 5 月 12 日 15:00-17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待人员姓 | 董事长/总经理 吴群 | | 名 | 副总经理/首席财务官 张勇 | | | 财务负责人 刘丽华 | | | 独立董事 万遂人 | | | 董事/董事会秘书 王瑞洁 | | | 公司于 2023 年 5 月 12 日 15:00-17:00，通过深圳市全景网络有限公司提供的网上平 | | | 台（https://ir.p5w.net）采用网络远程形式举办 2022 年度公司业绩说明会，投资者对 | ...

江苏鱼跃医疗设备股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布《2022 年年度报告》全文及摘要，为广大投资者能进一步了解公司经营 情况，公司定于 2023 年 5 月 12 日（星期五）下午 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长/总经理吴群先生、公司副 总经理/首席财务官张勇先生、公司财务负责人刘丽华女士、公司独立董事万遂 人先生、公司董事/董事会秘书王瑞洁女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 11 日（星期四）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入 问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问 题进行回答。欢迎广大投资者积极参与本次业绩说明会。 证券代码 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,702,565,759.46, representing a 48.41% increase compared to CNY 1,821,064,321.07 in the same period last year[4] - Net profit attributable to shareholders was CNY 713,524,000.08, up 53.79% from CNY 464,412,551.72 year-on-year[4] - The net profit after deducting non-recurring gains and losses reached CNY 703,197,797.43, marking a 79.18% increase from CNY 392,890,525.95 in the previous year[4] - Basic earnings per share rose to CNY 0.7186, reflecting a 55.21% increase from CNY 0.4634 in the previous year[4] - The operating profit for Q1 2023 was CNY 865.19 million, significantly higher than CNY 545.42 million in Q1 2022, reflecting a growth of 58.6%[16] - The company reported a total comprehensive income of CNY 707.99 million for Q1 2023, compared to CNY 459.90 million in Q1 2022, an increase of 54.0%[17] Cash Flow and Assets - The net cash flow from operating activities was CNY 815,331,594.82, a significant increase of 97.94% compared to CNY 411,916,788.95 in the same quarter last year[4] - Cash and cash equivalents in current assets were CNY 641,237,591.56, a significant increase from CNY 81,746,236.98 in the previous period[14] - The cash and cash equivalents at the end of Q1 2023 were CNY 3.64 billion, a decrease from CNY 2.45 billion at the end of Q1 2022[19] - The company experienced a net cash outflow from investing activities of CNY 1.55 billion in Q1 2023, compared to an outflow of CNY 471.16 million in Q1 2022[19] - Total assets at the end of the reporting period were CNY 15,416,068,458.54, a 2.06% increase from CNY 15,095,211,328.39 at the end of the previous year[4] Liabilities and Equity - Total liabilities decreased to CNY 4,635,568,244.60 from CNY 5,039,109,299.59, indicating a reduction of 8.0%[14] - The company's total equity increased to CNY 10,780,500,213.94, up from CNY 10,066,485,523.85, representing a growth of 7.1%[14] - The total liabilities at the end of Q1 2023 were CNY 4.76 billion, reflecting an increase from CNY 3.12 billion at the end of Q1 2022[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 77,627, with the largest shareholder, Jiangsu Yuyue Technology Development Co., holding 245,983,450 shares, representing 24.54% of the total shares[9] - Jiangsu Yuyue Technology Development Co. holds a total of 245,983,450 shares, accounting for 24.54% of the company's total equity, with 21 million shares pledged and 2 million shares frozen[10] - The top ten shareholders include both individual and institutional investors, with the largest individual shareholder, Wu Guangming, holding 10.32% of the shares[9] Expenses and Costs - Total operating costs for Q1 2023 were CNY 1,848,004,283.26, up 37.7% from CNY 1,342,363,107.41 in Q1 2022[15] - The company experienced a 51.62% increase in selling expenses, attributed to expanded sales efforts and increased advertising expenditures[7] - Research and development expenses amounted to CNY 135,236,278.10, slightly increasing from CNY 129,004,920.41 year-over-year[15] Regulatory and Market Developments - The company faced an administrative penalty of RMB 2.7 million from the Zhenjiang Market Supervision Administration for regulatory violations[11] - The company received a medical device registration certificate for its 14-day non-calibrated Continuous Glucose Monitoring (CGM) system on March 15, 2023, marking a significant breakthrough in diabetes care solutions[11] - The company aims to enhance its market presence by leveraging the advantages of its new CGM product in clinical effectiveness, comfort, portability, safety, and digital management[11] Asset Management - The company reported cash and cash equivalents of approximately RMB 3.72 billion, a decrease from RMB 4.84 billion in the previous period[12] - Accounts receivable increased to RMB 809.65 million from RMB 646.77 million, indicating a growth of approximately 25.1%[12] - Inventory decreased to RMB 1.32 billion from RMB 1.51 billion, reflecting a decline of about 12.4%[12] - The company’s financial assets held for trading increased to approximately RMB 2.94 billion from RMB 2.51 billion, showing a growth of about 16.9%[12] Impairment and Goodwill - The company reported a 9236.62% increase in asset impairment losses, mainly due to increased inventory write-downs and impairment provisions for long-term assets[8] - The company’s goodwill stood at CNY 1,109,753,277.27, showing a slight increase from CNY 1,109,596,428.05 year-over-year[14]

Financial Performance - The company's operating revenue for 2022 was CNY 7,101,679,159.74, representing a 3.01% increase compared to CNY 6,894,308,112.28 in 2021[6]. - The net profit attributable to shareholders for 2022 was CNY 1,595,037,435.14, an increase of 7.60% from CNY 1,482,421,641.48 in 2021[6]. - The net cash flow from operating activities increased by 91.88% to CNY 2,304,919,408.76 in 2022, compared to CNY 1,201,201,633.89 in 2021[6]. - The total assets at the end of 2022 reached CNY 15,095,211,328.39, a 25.82% increase from CNY 11,997,858,899.82 at the end of 2021[6]. - The net assets attributable to shareholders increased by 19.20% to CNY 9,860,018,658.01 at the end of 2022, compared to CNY 8,272,114,352.19 at the end of 2021[6]. - The basic earnings per share for 2022 was CNY 1.61, an increase of 8.05% from CNY 1.49 in 2021[6]. - The company achieved total revenue of 7.102 billion yuan in 2022, representing a year-on-year growth of 3.01%[52]. - Operating profit reached 1.842 billion yuan, an increase of 9.11% compared to the previous year[52]. - The company reported a total revenue of 3.740 billion in 2022, maintaining a steady performance compared to previous years[116]. Dividend Policy - The company reported a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares (including tax), amounting to a total cash dividend of approximately 612.71 million CNY for the year[142][143]. - The company reported a total distributable profit of approximately 5.84 billion CNY, with cash dividends accounting for 100% of the profit distribution[143]. - The estimated total cash dividend for 2022 is RMB 597,748,057.20, based on the adjusted total share capital[146]. - The company has no plans for stock dividends, focusing solely on cash dividends for shareholders[142]. Market Position and Growth Opportunities - The company is positioned in a growing medical device market, driven by factors such as GDP growth, aging population, and increasing healthcare demands[34]. - The company anticipates continued growth opportunities in the medical device sector, supported by favorable government policies and increasing R&D investments[35]. - The domestic market for home respiratory devices is still in the development stage, with a low penetration rate, but is expected to grow significantly due to increasing chronic respiratory disease patients and enhanced health management awareness[38]. - The number of diagnosed diabetes patients in China reached 116 million in 2019, projected to reach 200 million by 2030, driving demand for blood glucose monitoring devices[39]. - The company is focusing on expanding its product lines and enhancing its research and development capabilities in the medical device sector[119]. Research and Development - The company has established R&D centers in multiple locations, including Germany and Taiwan, to enhance innovation capabilities[51]. - Research and development expenses increased by 16.62% to ¥496 million, reflecting the company's commitment to innovation[57]. - The company is focusing on R&D for key technologies in diagnostic test strips, which will enhance its product competitiveness in the market[69]. - The company is enhancing its product competitiveness through technology upgrades and optimization of existing blood glucose test strips, including the dehydrogenase and oxidase types, to meet new national standards[70]. - R&D investment increased to ¥496.40 million in 2022, up 16.62% from ¥425.67 million in 2021, representing 6.99% of total revenue[74]. Corporate Governance - The company has maintained a strong governance structure, ensuring compliance with relevant laws and regulations, and has no significant discrepancies in governance practices[111]. - The company operates independently from its controlling shareholders in terms of business, assets, personnel, and finances, ensuring complete operational autonomy[112]. - The company has established independent personnel management systems and does not allow interference from controlling shareholders in its management decisions[113]. - The board of directors includes a diverse group of members, with the chairman and general manager holding 77,389,840 shares[115]. - The company is committed to transparency, with all board meeting resolutions disclosed in a timely manner[131]. Employee Welfare and Training - The total number of employees at the end of the reporting period was 6,362, with 2,899 in the parent company and 3,463 in major subsidiaries[139]. - The employee composition includes 2,664 production personnel, 1,482 sales personnel, and 1,137 technical personnel, reflecting a diverse skill set[139]. - The company emphasizes a diverse training program for employees, including overseas training and specialized courses from prestigious institutions[141]. - The company has established a comprehensive labor contract system and provides various social insurance benefits to all employees[161]. - The company emphasizes employee welfare, organizing various recreational activities and providing support for employees in need through the "Yuyue Love Fund"[162]. Strategic Partnerships and Acquisitions - The company has completed several acquisitions, including Zhejiang Kailite and Shanghai Zhongyou, to expand its product offerings[50]. - The company is actively seeking strategic partnerships for international market expansion, tailoring its approach to different countries' medical needs and cultural contexts[102]. - The company has completed the acquisition of a local medical device firm, enhancing its product portfolio and market presence[126]. - Jiangsu Yuyue plans to enter new markets, targeting Southeast Asia and Europe, with an expected market entry by Q3 2023[126]. Environmental Responsibility - The company actively promotes green practices and has implemented measures to reduce carbon emissions and improve resource efficiency[157]. - The company is committed to environmental responsibility, promoting energy efficiency and waste management, and has implemented paperless office practices[163]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[157]. Financial Management - The company is enhancing its cash flow management and increase the proportion of prepayment and cash delivery models in its operations[74]. - The company is actively managing its financial assets with no reported impairments, reflecting effective risk management practices[194]. - The company has not engaged in any major related party transactions during the reporting period[180]. - The company has no non-operating fund occupation by controlling shareholders or other related parties[172].

Financial Performance - Q3 2022 revenue was CNY 1,563,475,489.70, a decrease of 8.97% year-over-year, while year-to-date revenue reached CNY 5,116,277,433.29, down 3.65% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was CNY 347,595,835.66, a decline of 10.61% year-over-year, with year-to-date net profit at CNY 1,135,461,466.82, down 15.99%[3] - Basic earnings per share for Q3 2022 was CNY 0.3469, reflecting an 11.73% decrease compared to the same period last year[3] - Total revenue for the third quarter was CNY 5,116,277,433.29, a decrease of 3.65% compared to CNY 5,310,255,530.07 in the same period last year[15] - The total operating profit for Q3 2022 was approximately CNY 1.28 billion, a decrease of 16.9% compared to CNY 1.54 billion in Q3 2021[16] - Net profit attributable to shareholders of the parent company was CNY 1.14 billion, down 16.0% from CNY 1.35 billion in the same period last year[17] - The company reported a total comprehensive income of CNY 1.11 billion, a decrease of 17.2% from CNY 1.35 billion in Q3 2021[17] - Basic and diluted earnings per share were both CNY 1.1332, down from CNY 1.3609 in Q3 2021[17] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period increased by 7.20% to CNY 1,166,050,200.60[3] - The company reported a net investment income of CNY 58,637,340.92, down from CNY 79,936,438.87 in the previous year[15] - Cash inflow from investment activities totaled CNY 6.52 billion, an increase of 17.4% compared to CNY 5.55 billion in Q3 2021[19] - The net cash flow from investment activities was negative at CNY -75.1 million, an improvement from CNY -1.50 billion in the same period last year[19] - Cash and cash equivalents at the end of the period reached CNY 3.45 billion, up 30.6% from CNY 2.64 billion at the end of Q3 2021[19] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 13,215,428,898.56, representing a 10.15% increase from the end of the previous year[3] - Total liabilities amounted to CNY 3,912,192,317.29, compared to CNY 3,568,221,107.80, indicating an increase of 9.63%[14] - The company's equity attributable to shareholders rose to CNY 9,172,679,096.23 from CNY 8,272,114,352.19, a growth of 10.87%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 69,752, with the top ten shareholders holding significant stakes[8] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of shares, amounting to 245,983,450 shares, while Wu Guangming holds 10.32% with 103,438,537 shares[9] - The company has repurchased a total of 12,852,383 shares, representing 1.28% of the total share capital, with a total transaction amount of approximately 364.91 million RMB[10] - The first lock-up period for the employee stock ownership plan has expired, allowing for the release of 3,311,108 shares, which is 0.33% of the total share capital[11] - The top ten shareholders include various institutional investors, with the largest being Jiangsu Yuyue Technology Development Co., Ltd. and several mutual funds[9] - The company has a total of 6,622,216 shares allocated to the employee stock ownership plan, which were transferred at a price of 22.50 RMB per share[11] - The maximum and minimum repurchase prices during the buyback were 29.87 RMB and 27.60 RMB per share, respectively[10] - The total number of preferred shareholders is zero, indicating no preferred shares are currently held[8] Operational Costs and Expenses - Operating costs increased to CNY 4,047,920,990.46, up 4.26% from CNY 3,882,930,768.81 in the previous year[15] - Research and development expenses rose to CNY 381,392,719.03, reflecting a 22.25% increase from CNY 311,814,885.80 year-over-year[15] - The company experienced a 790.64% increase in fair value gains compared to the same period last year, attributed to increased interest income from structured deposits[7] - The company’s financial expenses decreased by 494.92% year-over-year, mainly due to exchange gains from currency fluctuations[6] Other Information - The company plans to continue expanding its market presence and invest in new product development[15] - The company did not conduct any audited financial report for Q3 2022[20] - The company experienced a foreign currency translation loss of CNY 3.57 million, compared to a loss of CNY 7.17 million in the previous year[17] - Accounts receivable increased by 60.21% compared to the beginning of the period, indicating a rise in reasonable receivables from normal business operations[6]